[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assistance Publique - Hôpitaux de Paris\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":678},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,868,0,25,[9,53,79,103,131,157,179,205,233,260,285,311,340,368,397,426,450,479,504,535,560,582,611,634,657],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100053839","phase-1-study-evaluating-a-gene-therapy-for-ipex-syndrome-through-the-expression-of-foxp3-on-deficient-t-cells-to-produce-tregs-like-100053839",false,"NCT07697118","Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.","A Phase I\u002FII Open-label, Non-randomized, Monocentric, Single-arm Study Evaluating the Safety and Efficacy of Induced CD4+ Treg by LV Vector Transduction Expressing the FOXP3 cDNA (FOXP3-T4) in Patients With IPEX Syndrome","THERIPEX","Inclusion Criteria:\n\n* Male patients only\n* Patients aged from 1 - 45 years of age (the first three patients will be aged between 10 - 45 years of age)\n* Patient with IPEX syndrome caused by mutation of the FOXP3 gene\n* Patients are eligible from the second line of treatment onward, even those under controlled disease\n* Patient with recurrent IPEX symptoms, under immune suppressive medications\n* Patient for whom HSCT is not feasible or when no suitable compatible donor is available\n* Patients who have had prior allogeneic blood stem cell transplantation (HSCT) with engraftment failure defined as no intake of donor cells\n* Patient or parental, guardian's patient signed informed consent\n* Male participants of reproductive potential with a partner of childbearing potential (WOCBP): willing to use an effective method of contraception during the trial and for at least 12 months post-infusion\n* Affiliation to a French or European social security scheme\n\nExclusion Criteria:\n\n* Unwillingness to return for follow-up during the 2-year study and during the 15 years of long term follow up study.\n* Patient with short life expectancy\n* Patient on AME (state medical aid) (unless exemption from affiliation).\n* Diagnosis of a significant psychiatric disorder of the patient that could seriously impede the ability to participate in the study.\n* Eligible for an HLA matched sibling or matched unrelated donor blood stem cell transplant (HLA 10\u002F10) and be willing to undergo transplant.\n* Patients with uncontrolled or ongoing active infections.\n* HIV-1 or 2 or HTLV-1 infections.\n* Patients with severe IPEX clinical presentation needing a rapid allogeneic HSCT treatment within 3 months.\n* Patients with known history of hypersensitivity to IL-2 or any component of the formulation (mannitol, sodium lauryl sulfate, monosodium phosphate dehydrate, disodium phosphate dehydrate, glucose.","MALE","1 Year","45 Years",{"count":22,"type":23},5,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and efficacy of FOXP3-T4 (an autologous gene therapy) alone or in combination with low-dose IL-2 for the treatment of IPEX syndrome. The therapy involves the transplantation of autologous CD4+ T-cells transduced ex vivo with the LV-EF1a-FOXP3-LNGFR lentiviral vector. The study follows a staggered approach: the first two patients will receive FOXP3-T4 monotherapy. Subsequent patients will receive FOXP3-T4 followed if needed by low-dose IL-2 treatment consisting of a daily dose for 5 days, then weekly administrations for 3 months.\n\nThe study aims to stabilize autoimmune manifestations and potentially cure the underlying disease, ultimately allowing for the discontinuation of ongoing immunosuppressive treatments.",[30],"The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3",[32,33,34,35,36,37,38,39],"Autoimmune diseases","Genetic diseases","Gene therapy","Lentiviral vector","Immune dysregulation Polyendocrinopathy Enteropathy X-linked","Autoimmunity-Immunodeficiency Syndrome","Forkhead Box Protein 3","Low-dose IL-2","NOT_YET_RECRUITING","2026-07-06",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":23},"2026-09",{"date":48,"type":23},"2029-01",{"name":50,"class":51},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":52},"100054067","a-comparative-study-of-fusional-vergence-according-to-ocular-dominance-in-healthy-subjects-100054067","NCT07697131","A Comparative Study of Fusional Vergence According to Ocular Dominance in Healthy Subjects","ECAFOSS","Inclusion Criteria:\n\n* Adults between the ages of 18 and 35 with no known eye conditions, with or without ametropia. If ametropia is present: it must be corrected\n* Subjects with no history of eye surgery, including refractive surgery\n* Subjects who have been informed about the study and have freely and knowingly consented to participate in the study and to the collection of data\n\nExclusion Criteria:\n\n* Subjects with strabismus\n* Subjects with visual acuity of less than 20\u002F20; or anisometropia",true,"ALL","18 Years","35 Years",{"count":65,"type":23},60,"OBSERVATIONAL","In orthoptics, fusional vergence (FV) measurement is one of the key tests used to assess fusion ability. These amplitudes are generally reduced in individuals with convergence insufficiency. Fusional vergence are quantified by placing a prism bar randomly in front of one eye-first for distance vision and then for near vision. Rehabilitation exercises using the prism bar are also performed in the same manner.\n\nDepending on orthoptic practice, the prism bar is placed in front of the left eye or the right eye, in a dogmatic manner, or in front of the right eye, in a conventional manner, without any study providing any justification. However, some practitioners report interocular differences when measuring fusion amplitudes depending on which eye is prismed, while others do not.\n\nThe hypothesis put forward is that, in individuals with an interocular difference in fusional vergence, ocular dominance (sensory and motor) could be the cause of this measurement discrepancy.\n\nThe objective is therefore to compare the difference in fusional vergence depending on whether the dominant or non-dominant eye is tested, using a randomized order of eyes and tests.\n\nIf this hypothesis is confirmed (greater fusional vergence when tested on the dominant eye), this would: (1) enhance our understanding of fusion mechanisms, (2) provide more targeted insights for the assessment, quantification, and rehabilitation of fusional vergence to improve the effectiveness of orthoptic intervention.",[69],"No Eye Disorder",[71,72,73],"Fusional vergence","Ocular dominance","Orthoptic practice",{"date":43,"type":44},{"date":46,"type":23},{"date":77,"type":23},"2027-07",{"name":50,"class":51},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100053975","effect-of-adding-vasopressin-on-cardiac-output-blood-pressure-diuresis-and-tissue-perfusion-indices-in-patients-with-septic-shock-100053975","NCT07697144","Effect of Adding Vasopressin on Cardiac Output, Blood Pressure, Diuresis, and Tissue Perfusion Indices in Patients With Septic Shock","VASO-PHENO","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Hospitalized in an intensive care unit;\n* Presenting with septic shock according to Sepsis-3 criteria;\n* For whom the treating clinician wishes to initiate vasopressin as second-line therapy as part of routine care;\n* Undergoing hemodynamic monitoring with a PiCCO2 device (Pulsion Medical Systems, Getinge, Feldkirchen, Germany) or pulmonary artery catheterization as part of routine care.\n\nExclusion Criteria:\n\n* Patient already receiving vasopressin;\n* Pregnancy;\n* Patient under legal protection;\n* Patient unwilling to participate in the study.",{"count":87,"type":23},200,"In patients with septic shock, vasopressin is increasingly used in combination with norepinephrine, but its timing of initiation remains heterogeneous and its clinical hemodynamic effects are still insufficiently characterized. Available data suggest variable responses, which may depend on the hemodynamic phenotype at the time of treatment initiation. In particular, the effects of vasopressin may differ according to the presence of preload dependency, baseline cardiac output, impaired systolic function, or baseline diastolic arterial pressure, reflecting the degree of vasoplegia. In this context, the VASO-PHENO study aims to provide a detailed and dynamic description of the early hemodynamic and clinical effects of vasopressin initiation in septic shock.\n\nTo date, no clinical study has systematically and dynamically evaluated the effects of vasopressin on central and peripheral hemodynamic parameters according to the hemodynamic profile at the time of its initiation. Describing these effects appears essential to better understand the variability in clinical responses and to contribute to a more rational and personalized approach to vasopressor escalation in septic shock.",[90],"Septic Shock and Use of Vasopressin",[92,93,94,95],"Septic shock","Vasopressin","Cardiac output","Hemodynamic",{"date":43,"type":44},{"date":98,"type":23},"2026-08-01",{"date":100,"type":23},"2029-09-01",{"name":50,"class":51},8,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":60,"sex":110,"minAge":62,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":52},"100638427","breast-cancer-risk-assessment-in-night-shift-workers---implementation-of-a-personalized-consultation-100638427","NCT07630935","Breast Cancer Risk Assessment in Night Shift Workers - Implementation of a Personalized Consultation","NIGHT-SCAN","Inclusion Criteria:\n\n* Female participants aged 18 years or older\n* Night shift workers at Pitié-Salpêtrière Hospital\n* Attending consultation for breast cancer risk assessment PGRC\n* Affiliated with a social security system\n* No personal history of breast cancer\n* Provided informed consent (non-opposition procedure according to French regulations)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Individuals under legal protection or deprived of liberty\n* Individuals without standard health insurance coverage","FEMALE",{"count":112,"type":23},100,"This study evaluates adherence to a personalized prevention plan in female night shift workers at increased risk of breast cancer. Night shift work is associated with circadian disruption and increased cancer risk, as well as cardiovascular and reproductive health risks.\n\nParticipants attend an initial consultation including clinical assessment and development of a personalized prevention plan targeting modifiable risk factors such as alcohol consumption, physical activity, smoking, diet, and weight.\n\nFollow-up is conducted remotely over 5 years to assess adherence to recommendations and screening. Participant satisfaction and adherence to additional consultations are also evaluated.",[115],"Breast Neoplasms Diagnosis",[117,118,119,120,121,122],"Breast neoplasms","prevention & control Cancer prevention","Risk reduction behavior","Night shift work","Personalized prevention","Risk assessment","2026-06-29",{"date":125,"type":44},"2026-07-01",{"date":127,"type":23},"2026-06-15",{"date":129,"type":23},"2032-06-15",{"name":50,"class":51},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":61,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":52},"100620356","evaluation-of-therapeutic-adherence-among-patients-followed-in-the-department-of-hereditary-metabolic-diseases-at-necker-hospital-100620356","NCT07356557","Evaluation of Therapeutic Adherence Among Patients Followed in the Department of Hereditary Metabolic Diseases at Necker Hospital","OBSERVANCE MHM","Inclusion Criteria:\n\n* All patients followed in the Hereditary Metabolic Diseases department of Necker Hospital during their visit to the department for their usual care and having a specific daily oral medication treatment.\n* Children aged at least 7 years and adolescents\u002Fyoung adults\n* Holders of parental authority and children or adolescents or adults' patients informed and consenting to participate in the study\n\nExclusion Criteria:\n\n* Metabolic disease without oral medication (intravenous treatments, amino acid mixtures, and dietary regimens are not evaluated).\n* Patient and parents not proficient in French.\n* Refusal by the patient's holders of parental authority or adult patient to participate in the study and\u002For refusal of the child\u002Fadolescent.","7 Years","20 Years",{"count":87,"type":23},"The purpose of this study is to evaluate treatment adherence among patients followed in the Department of Inherited Metabolic Diseases at Necker Hospital, in order to assess the need for implementing a therapeutic education workshop focused on medication adherence.",[143],"Metabolic Diseases",[145,146,147,148],"Metabolic disease","Daily oral drug treatment","Medication adherence","Therapeutic education workshop","RECRUITING",{"date":151,"type":44},"2026-06-30",{"date":153,"type":44},"2026-02-23",{"date":155,"type":23},"2028-02-23",{"name":50,"class":51},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":61,"minAge":164,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":52},"100614476","study-of-skin-and-gut-microbiome-in-a-skin-condition-involving-skin-barrier-impairment-and-allergic-symptoms-netherton-syndrome-100614476","NCT07280091","Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome","DERMABIOTE","Inclusion Criteria:\n\nGroup A:\n\n* Children aged 10 years and older and adults with confirmed Netherton syndrome diagnosed at age 10 years or older (clinical and histological and\u002For molecular)\n* Patients and legal guardians informed about the study and not opposed to participation in the study\n\nGroup B:\n\n* Children aged 10 years and older and adults with no skin barrier impairment, dermatosis, inflammatory disease, or autoimmune disease.\n* Subjects and legal guardians informed about the study and who do not object to participation in the study.\n\nExclusion Criteria:\n\n* Refusal by parents\u002Fguardians, children, adolescents, or adults.\n* General or local antibiotic therapy within the month preceding the consultation.","10 Years",{"count":166,"type":23},30,"It is proposed to conduct an exploratory study to analyze the skin, intestinal, and salivary microbiome, as well as the skin mycobiome and virome, of patients (adolescents and young adults) with Netherton syndrome, a condition characterized by an impaired skin barrier that most likely promotes the development of allergic manifestations.\n\nThe study will be conducted on patients with Netherton syndrome and control subjects in order to investigate possible correlation factors between the three microbiomes and identify which ones.",[169],"Netherton Syndrome",[171,172],"Netherton syndrome","skin microbiome",{"date":151,"type":44},{"date":175,"type":44},"2026-05-26",{"date":177,"type":23},"2028-05",{"name":50,"class":51},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":61,"minAge":4,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":24,"phases":189,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":52},"100613127","assessment-of-airway-opening-pressure-in-invasively-ventilated-children-100613127","NCT07262541","Assessment of Airway Opening Pressure in Invasively Ventilated Children","AOP-KID","Inclusion Criteria:\n\n* Minor patients weighing more than 5 kg, hospitalized in the pediatric intensive care unit at Necker-Enfants Malades Hospital and receiving invasive ventilation. To assess patients with acute respiratory distress syndrome, the PALICC-2 criteria are used.\n* Holders of parental authority must be informed and consent to their child's participation in the study.\n* The patient must be passively ventilated to ensure reliable measurements. This means that the patient must not be spontaneously ventilating and must be completely passively ventilated by the ventilator (no respiratory effort during long-term inflation).\n\nExclusion Criteria:\n\n* Respiratory mechanics preventing interpretation of maneuvers (flow too low and\u002For resistance too high)\n* Patient \\\u003C 5 kg\n* Refusal by those with parental authority\n* Patient not affiliated with social security\n* Patient receiving AME (Medical Aid for Life)\n* Contraindication or impossibility of performing static respiratory mechanics measurements: pneumothorax or pleural leak, head trauma or threatening HTIC, unstable patient with SpO2 \\\u003C 88%, patient receiving nitric oxide (NO) (circuit leaks) or other circuit leaks or patient leaks \\> 20% displayed on the ventilator","17 Years",{"count":188,"type":23},50,[190],"NA","Acute respiratory distress syndrome (ARDS) in children is associated with significant morbidity and mortality. Current studies seek to individualize the management of children by defining several phenotypes, based until now mainly on clinical presentation. A better understanding of the respiratory mechanics of each patient could allow the individualization of other phenotypes and adapt their management with individualized ventilation. The method for detecting airway opening pressure (AOP) in children has not yet been validated and the reference methods in adults are difficult to apply in children due to their physiological particularities.\n\nThe main objective of the study is to evaluate the feasibility of two methods for measuring airway opening pressure in invasively ventilated pediatric patients.",[193],"Acute Respiratory Distress Syndrome in Children",[195,196,197,198],"Acute respiratory distress syndrome","Invasively ventilated children","Airway opening pressure (AOP) detection","Children",{"date":151,"type":44},{"date":201,"type":44},"2026-02-02",{"date":203,"type":23},"2031-02",{"name":50,"class":51},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":215,"conditions":216,"keywords":224,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":52},"100593731","epithelial-dysmetabolism-and-renal-fibrosis-in-anca-vasculitis-100593731","NCT07010250","Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis","PROTECT-Fi","Inclusion Criteria:\n\n* Patients with an indication for initial diagnostic PBR on native kidney\n* 18 ans ≥ Age ≤ 90 ans\n* Affiliation to french health insurance\n* Patient having given consent\n\nFor the ANCA vasculitis group:\n\n• Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO)\n\nFor the control groups:\n\n• Diagnosis retained after the renal biopsy\n\n* Interstitial Nephritis\n* Or glomerular nephropathy such as minimal change nephropathy\n* Or Segmental hyalinosis in itscollapsing form\n* Or Extramembranous Glomerulopathy,\n* Or glomerulopathy with mesangial IgA deposits\n* Or diabetic nephropathy.\n\nExclusion Criteria:\n\n* Kidney transplant patient\n* Patient on dialysis (hemodialysis or peritoneal dialysis)\n* Patient under legal protection, guardianship or curatorship\n* Pregnancy or breastfeeding\n* Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.","90 Years",{"count":214,"type":23},146,"The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.",[217,218,219,220,221,222,223],"ANCA Associated Vasculitis","Extramembranous Glomerulopathy","Nephrotic Syndrome, Minimal Change","Interstitial Nephritis","IgA Nephropathy","Segmental Hyalinosis","Diabetic Nephropathies",[225,226],"nephropathy","cohort",{"date":151,"type":44},{"date":229,"type":44},"2025-11-03",{"date":231,"type":23},"2029-11-02",{"name":50,"class":51},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":244,"conditions":245,"keywords":250,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":259},"100573579","improving-patients-adherence-to-their-chronic-treatments-by-implementing-a-simple-standardized-and-redundant-message-delivered-by-healthcare-professionals-100573579","NCT06748118","Improving Patients' Adherence to Their Chronic Treatments by Implementing a Simple, Standardized and Redundant Message Delivered by Healthcare Professionals.","Improving Patients' Adherence to Their Chronic Treatments by Implementing a Simple, Standardized and Redundant Message Delivered by Healthcare Professionals: a Stepped-wedge Multicenter Randomized Trial","MAPS","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Affiliated to the French social security system\n* Followed in hospital for a chronic pathology within a formalized care pathway\n* Having signed a consent form to participate in the study.\n\nExclusion Criteria:\n\n* Patients included in the control period.\n* Patients under guardianship.\n* Pregnant or breast-feeding patients.\n* Patients taking part in research on compliance",{"count":242,"type":23},1210,[190],"The primary objective in this study is to achieve a 15% 6-month improvement in therapeutic adherence among patients with chronic pathologies, thanks to a simple, standardized and redundant message delivered by healthcare professionals during consultations\u002Finterviews Trained healthcare professionals deliver a simple, standardized and redundant 3-point message to patients, based on the levers of action concerning therapeutic adherence. This message is delivered with the aim of modifying the patient's behavior with regard to treatment intake.",[246,247,248,249],"Chronic Disease","Therapeutic Adherence","Training Group, Sensitivity","Delivery Simple, Standardized & Redundant Message to Patient",[251,252],"intervention study","stepped wedge study",{"date":125,"type":44},{"date":255,"type":44},"2026-03-18",{"date":257,"type":23},"2028-03",{"name":50,"class":51},10,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":61,"minAge":4,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":52},"100540890","optimization-of-routine-obstetric-and-neonatal-care-in-the-management-of-severe-perinatal-asphyxia-in-term-or-near-term-newborns-analysis-of-sub-optimal-care-100540890","NCT06322732","Optimization of Routine Obstetric and Neonatal Care in the Management of Severe Perinatal Asphyxia in Term or Near-term Newborns: Analysis of Sub-optimal Care","OptiNeoCare","Inclusion Criteria:\n\n\\- Newborn at or near term (≥ 36 weeks of amenorrhea), considered to be alive at the onset of labor and presenting severe perinatal asphyxia\n\nSevere perinatal asphyxia is considered if\n\n1. Severity in its impact on the newborn:\n\n   • a neonatal death during the initial hospitalization, since birth and before a possible return home, before D28 \".\n\n   OR\n   * moderate to severe anoxic-ischemic encephalopathy OR\n   * a newborn hospitalized in the first week of life for hypoxic-ischemic encephalopathy or convulsions related to a perpartum event.\n\n   AND\n2. Biological perinatal asphyxia:\n\n   * a pH (arterial or, failing that, venous) ≤ 7.10 or base deficit ≥ 16mmol\u002FL or lactates ≥ 11mmol\u002FL during the first three hours of life OR\n   * In the absence of biological documentation of metabolic acidosis, an Apgar ≤ 5 to 5 minutes of life or the need for neonatal resuscitation (ventilatory support at birth and Apgar score ≤ 7 to 10 minutes of life).\n   * If none of the biological elements are available in the file, keep the clinical inclusion criteria below (In the absence of biological and clinical Apgar data (home delivery type), inclusion may be based on neonatal outcome (death - hypoxic ischemic encephalopathy - neonatal convulsions).\n\nExclusion Criteria\n\n* Fetal death in utero prior to hospital admission\n* Medical termination of pregnancy\n* Severe malformations with potential impact on child survival and development.\n* Neonatal encephalopathy not due to perinatal asphyxia","1 Month",{"count":269,"type":23},336,"The purpose of this study is to identify and analyze suboptimal perinatal (obstetric-pediatric) care in the occurrence and management of severe perinatal asphyxia or death of the newborn at or near term.\n\nPerinatal asphyxia is a serious and often unexpected pathology, requiring urgent multidisciplinary care (obstetric - pediatric - intensive care, etc.) with a high level of technical expertise and care coordination. Because of its rarity and complexity, it may be subject to suboptimal care.\n\nThe aim of this study is to provide feedback within the center itself, coupled in 1\u002F3 of cases with a confidential investigation into the search for and understanding of suboptimal care.\n\nPrimary endpoint:\n\nFrequency of optimal or non-optimal maternal and neonatal management of hypoxic-ischemic encephalopathy (AIE) or neonatal death related to severe perinatal asphyxia.",[272],"Perinatal Asphyxia",[274,275,276,277,278],"Hypoxic-ischemic encephalopathy","perinatal asphyxia","neonatal death","suboptimal care","confidential inquiry",{"date":125,"type":44},{"date":281,"type":44},"2025-05-05",{"date":283,"type":23},"2027-01",{"name":50,"class":51},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":24,"phases":296,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":7},"100511985","phase-3-a-trial-to-evaluate-the-efficacy-of-pioglitazone-to-promote-renal-tolerance-in-anca-associated-vasculitis---renato-trial-100511985","NCT05946564","A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial","A Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO","RENATO","Inclusion Criteria:\n\n* Newly-diagnosed or relapsing ANCA-associated vasculitis, i.e. granulomatosis with polyangitis (GPA) or microscopic polyangiitis (MPA), according to ACR 1990 criteria and\u002For revised Chapel Hill Consensus Conference definitions and\u002For European Medical Agency algorithm, with an active disease defined as a BVAS ≥3\n* Presence of proteinuria (UPCR \\>300 mg\u002Fg), haematuria (\\>10 RBC\u002Fhpf), and eGFR ≥15 mL\u002Fmin\u002F1.73 m2 (CKD-EPI formula) at inclusion (\\\u003C1 month)\n* Recent (\\\u003C4 weeks) renal biopsy that confirms active renal involvement of ANCA-associated vasculitis\n* Patients aged of 18 to 80 years\n* Participant written informed consent prior to participation in the study\n* Participants affiliated to a French health insurance system (registered or being a beneficiary of such a scheme)\n\nExclusion Criteria:\n\n* Alveolar haemorrhage requiring pulmonary ventilation support at inclusion\n* Patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss)\n* Active cancer (except non-melanoma skin cancer) within the past 24 months\n* Active severe bacterial, viral or fungal infectious disease\n* Past history of bladder or urinary tract cancer\n* History of Class 3\u002F4 congestive heart failure symptoms, any time\n* History of Class 2 heart failure symptoms within the past 3 months and\u002For ejection fraction \\\u003C40% on recent echocardiography (\\\u003C1 month)\n* Transaminases levels above 2 times the normal range value (\\\u003C1 month) or any severe chronic liver disease\n* Positive serology for HIV, HBV (Ag HBs positivity) or active HCV infection at inclusion\n* Presence of neutropenia \\\u003C1000 cells\u002Fl (\\\u003C1 month)\n* History of intolerance to any thiazolidinedione (including Pioglitazone), to rituximab or any excipient listed in SmPc\n* Diabetic ketoacidosis, any time\n* A pre-existing or an important risk of new-onset macular edema (confirmed by an ophthalmological examination)\n* Pregnant or breast-feeding women, or desire to become pregnant within 24 months All women of childbearing potential (WOCBP) are required to have a negative pregnancy test before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using an effective method of birth control from the date of consent through the end of the study and another 12 months after (or 12 months after the last rituximab infusion in case of premature termination): Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (Oral, Intravaginal, Transdermal); Progestogen-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner\n* Severe neurologic or psychiatric disease (e.g., dementia or schizophrenia)\n* Kidney transplant recipients\n* Cyclophosphamide or rituximab (dose \\> 375 mg\u002Fm2) use within 26 weeks prior to screening; if on azathioprine, mycophenolate mofetil or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the first rituximab dose. Patients that have initiated induction therapy with rituximab for the actual flare, can be included in the present study within 48h following the first rituximab infusion\n* Intravenous glucocorticoids, \\>3000 mg methylprednisolone equivalent, within 4 weeks prior to screening\n* Patients who have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening\n* Current participation in another research study involving a therapeutic intervention. Participation to an observational research, or a non-interventional research is allowed\n* Patients under guardianship or curators and protected adults\n* Patients not able to understand and follow study procedures\n* Patients on AME (Aide Médicale de l'Etat = State Medical Assistance)","80 Years",{"count":295,"type":23},126,[297],"PHASE3","The RENATO trial is a multicenter randomized controlled trial that evaluates the efficacy of pioglitazone to improve renal outcomes in ANCA-associated vasculitis.\n\nPatients with biopsy-proven kidney involvement of ANCA vasculitis will be included in this trial at diagnosis. All patients will receive a standard of care immunosuppressive (SOC) therapy combining corticosteroids and rituximab (375 mg\u002Fm2\u002Fweek for 4 consecutive weals followed by 500 mg re-infusion every 6 months). They will be randomized 1:1 to receive either pioglitazone 30 mg\u002Fday or placebo for 6 months, on top of SOC. The primary objective of this trial is to demonstrate that pioglitazone reduces kidney damage, reflected by the early improvement of proteinuria and serum creatinine levels. The secondary objectives will be to assess the efficacy of this drug on the reduction of hypertension and metabolic effects of glucocorticoids, to measure its impact on vasculitis activity and to evaluate the safety profile of pioglitazone in this population.",[217,300,301],"Rapidly Progressive Glomerulonephritis","Crescentic Glomerulonephritis",[303,304],"ANCA","vasculitis",{"date":125,"type":44},{"date":307,"type":44},"2023-10-24",{"date":309,"type":23},"2028-11",{"name":50,"class":51},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":319,"targetDuration":164,"studyType":66,"phases":4,"briefSummary":321,"conditions":322,"keywords":328,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":4},"100644842","prospective-cohort-of-acute-cardiology-referrals-in-an-ambulatory-day-hospital-setting-100644842","NCT07675434","Prospective Cohort of Acute Cardiology Referrals in an Ambulatory Day-Hospital Setting","CESAR Study: Prospective Cohort of Consecutive Patients Undergoing Cardiologic Evaluation in a Specialized Ambulatory Referral Unit","CESAR","Inclusion Criteria:\n\n\\- The study will include all consecutive patients referred to ambulatory day-hospital unit for suspicion of acute or sub-acute cardiovascular disease at the Cardiology Department of Lariboisière University Hospital.\n\nExclusion Criteria:\n\n* Patient unable to provide informed consent\n* Patient not affiliated to French social security",{"count":320,"type":23},25000,"Suspected acute or subacute cardiovascular diseases-including chest pain, dyspnea, and palpitations-are among the most common reasons for unscheduled emergency department visits and pre-hospital referrals. Despite this high clinical burden, the diagnostic yield is often limited, with a frequent mismatch between initial clinical suspicion and final diagnosis, contributing to substantial healthcare utilization and hospitalization rates. Current evidence is largely focused on specific conditions such as acute coronary syndromes, heart failure, arrhythmias, or pulmonary embolism, and rarely integrates the full spectrum of clinical, biological, and imaging data obtained during initial evaluation.\n\nTo address this gap, we will establish a prospective cohort of all consecutive patients referred to the ambulatory day-hospital cardiology unit at Lariboisière University Hospital. This unit acts as a specialized downstream referral structure within the emergency care pathway, receiving patients after triage by emergency physicians, pre-hospital regulation services (SAMU), mobile intensive care units (SMUR), or emergency departments. Although it does not capture all suspected cardiovascular emergencies, it represents a selected real-world population deemed to require specialized acute cardiology assessment.\n\nThe primary objective is to assess the frequency of cardiac conditions diagnosed in this cohort. Secondary objectives include characterization of patient profiles and diagnostic pathways; evaluation of the diagnostic and prognostic performance of clinical, biological, imaging, and multimodal parameters using final Heart Team diagnosis as reference; analysis of prior health history and healthcare utilization; and assessment of the medico-economic burden of suspected acute cardiovascular disease. The study will further support the development of a dedicated biobank and the validation of next-generation biomarkers, including AI-driven and voice-based markers, as well as decision-support algorithms for binary classification of cardiac involvement. Through integration of multimodal data and linkage with national health records, this approach aims to improve diagnostic accuracy, risk stratification, and understanding of the healthcare impact of acute cardiovascular presentations in a real-world setting.",[323,324,325,326,327],"Acute Coronary Syndromes","Heart Failure","Pulmonary Embolism, Deep Vein Thrombosis","HTN-Hypertension","Arrhythmia",[329,330,331,332,333],"Cardiovascular emergencies","Multimodality Imaging","Acute care","Prospective cohort","Biomarkers","2026-06-26",{"date":151,"type":44},{"date":98,"type":23},{"date":338,"type":23},"2041-08-01",{"name":50,"class":51},{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":349,"conditions":350,"keywords":355,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":367,"locationsCount":52},"100645419","effect-of-platelet-concentrate-transfusion-on-microcirculatory-endothelial-function-in-intensive-care-unit-100645419","NCT07682246","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT","EFFECT OF PLATELET CONCENTRATE TRANSFUSION ON MICROCIRCULATORY ENDOTHELIAL FUNCTION IN INTENSIVE CARE UNIT.","PLATOMIR","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Admitted to intensive care\n* Requires prophylactic platelet transfusion for thrombocytopenia\n* Enrolled in a social security program\n* No objection to participating in the study\n\nExclusion Criteria:\n\n* Recent platelet or red blood cell transfusion (\\\u003C 24 hours)\n* Need for urgent red blood cell transfusion due to active bleeding\n* Patient under guardianship or conservatorship\n* Significant peripheral edema",{"count":65,"type":23},"This study aims to investigate the impact of platelet concentrate (PC) transfusions on endothelial function and the systemic inflammatory response in thrombopenic patients admitted to intensive care who require prophylactic platelet transfusions.\n\nEndothelial function will be measured using a laser Doppler device coupled with an acetylcholine iontophoresis system that is applied to the skin.",[351,352,353,354],"Thrombocytopenia","Prophylactic Platelet Transfusion","Platelet Transfusion","Endothelial Function",[356,357,353,354,358,359,360,361],"ICU","intensive care","endothelial biomarkers","systemic inflammation","oxidative stress","peripheral tissue perfusion",{"date":363,"type":44},"2026-07-02",{"date":365,"type":23},"2026-07",{"date":77,"type":23},{"name":50,"class":51},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":377,"conditions":378,"keywords":380,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":396},"100644188","assessment-of-the-reproducibility-of-the-recruitment-to-inflation-ratio-ri-ratio-measurement-in-patients-with-acute-respiratory-distress-syndrome-100644188","NCT07666503","Assessment of the Reproducibility of the Recruitment-to-inflation Ratio (R\u002FI Ratio) Measurement in Patients With Acute Respiratory Distress Syndrome","RIRR","Inclusion Criteria:\n\n* Adult patient (age ≥ 18 years)\n* Patient hospitalized in the Intensive Care Unit (ICU) for acute respiratory distress syndrome (according to the Berlin definition), requiring invasive mechanical ventilation with deep sedation and controlled mechanical ventilation mode\n* Patient or next of kin informed about the study and not objecting to participation\n\nExclusion Criteria:\n\n* Undrained pneumothorax or any contraindication to a transient increase in airway pressure\n* Known or suspected intracranial hypertension\n* Patient under legal protection (e.g., guardianship)\n* Not affiliated with a social security system\n* Presence of spontaneous respiratory effort\n* Presence of a leak in the ventilatory circuit\n* Hemodynamic instability (e.g., uncontrolled shock, increasing vasopressor requirement)\n* Uncontrolled severe hypoxemia\n* Undrained pneumothorax or any contraindication to a transient increase in airway pressure\n* Known or suspected intracranial hypertension",{"count":376,"type":23},80,"Acute respiratory distress syndrome (ARDS) is a severe lung condition that often requires invasive mechanical ventilation in the intensive care unit. In these patients, setting the ventilator appropriately is essential to improve oxygenation while limiting ventilator-induced lung injury. One important ventilator setting is positive end-expiratory pressure (PEEP), which helps keep the lungs open. However, the optimal PEEP level may vary from one patient to another.\n\nThe recruitment-to-inflation ratio (R\u002FI ratio) is a bedside measurement used to estimate the potential for lung recruitment during a decrease in PEEP. It compares the compliance of the lung volume recruited by PEEP with the compliance of the already aerated lung. A higher R\u002FI ratio suggests that increasing PEEP is more likely to reopen collapsed lung units, whereas a lower R\u002FI ratio suggests limited recruitability and a higher likelihood that additional pressure would mainly distend lung areas that are already open. In clinical practice, the R\u002FI ratio is increasingly used to guide PEEP adjustment, with the aim of improving recruitment and oxygenation while avoiding unnecessary increases in airway pressure. However, although the R\u002FI ratio is used in routine care, there are currently no data demonstrating that this measurement is reproducible when repeated in the same patient under similar conditions.\n\nThe hypothesis of this study is that the R\u002FI ratio is reproducible when measured twice in the same patient under stable conditions, including no significant changes in ventilator settings, hemodynamic status, or ongoing treatments.\n\nThis prospective, multicenter, non-interventional study will include adult ICU patients with ARDS who are receiving invasive mechanical ventilation, deep sedation, and assist-control ventilation. For each patient, airway opening pressure will be assessed, and the R\u002FI ratio will be measured twice on the same day by a trained clinician, between 20 and 120 minutes apart, without changes in ventilator settings or treatments likely to influence the measurement.\n\nThe main objective is to evaluate the within-patient reproducibility of the R\u002FI ratio. Secondary objectives include describing changes in airway opening pressure and R\u002FI ratio over time, assessing the reproducibility of expired tidal volume during the maneuvers, and evaluating the clinical tolerance of these ventilatory measurements.\n\nThe study will include 80 patients across 4 French intensive care units. No additional intervention outside routine care will be performed. Clinical, ventilatory, and biological data already collected as part of usual care will be recorded.",[379],"Acute Respiratory Distress Syndrome (ARDS)",[381,382,383,384,385,386,387,388],"Mechanical Ventilation","Positive End-Expiratory Pressure","Lung Recruitment","Lung Recruitability","Respiratory Mechanics","Airway Opening Pressure","Reproducibility of Results","Intraclass Correlation Coefficient","2026-06-22",{"date":391,"type":44},"2026-06-24",{"date":151,"type":23},{"date":394,"type":23},"2027-06-30",{"name":50,"class":51},4,{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":24,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":52},"100635553","4d-flow-mri-assessment-of-portal-hypertension-and-tips-outcomes-in-cirrhosis-100635553","NCT07554183","4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis","Predicting Outcomes and Risk of Complications Related to Portal hyperTension by Non-invasive Assessment of Liver Flow With 4D MRI","PORTAL-4D","Inclusion Criteria:\n\nApplicable to both groups :\n\n1. Age ≥ 18 years\n2. Eligible to undergo MRI examination\n3. Prior clinical evaluation completed\n4. Covered by a national health insurance scheme or beneficiary thereof (excluding State Medical Aid AME)\n5. Patient informed and written informed consent obtained\n\n   Specific to the MASLD group :\n6. Indication for TIPS validated during a multidisciplinary team meeting and documented in the patient's medical record, including one of the following:\n\n   * Refractory ascites\n   * Hepatic hydrothorax\n   * Failure of secondary prophylaxis of variceal gastrointestinal bleeding\n   * Preemptive TIPS\n   * Preoperative TIPS\n\n   Specific to the MASLD group :\n7. Past or current exposure to metabolic risk factors (overweight, obesity, type 2 diabetes mellitus, arterial hypertension, dyslipidemia)\n8. Liver stiffness \\> 15 kPa measured by transient elastography\n9. Liver biopsy documenting steatosis with stage 3 fibrosis or cirrhosis\n10. Alcohol consumption \\\u003C 20 g\u002Fday for women and \\\u003C 30 g\u002Fday for men, assessed using validated routine clinical questionnaires\n\nExclusion Criteria:\n\nApplicable to both groups :\n\n1. Any contraindication to MRI (cardiac pacemaker, implantable cardioverter-defibrillator, cochlear implants, intraocular metallic foreign bodies, intracranial vascular clips).\n2. Prior liver transplantation.\n3. Pregnancy, breastfeeding, or women of childbearing potential not using effective contraception.\n4. Individual under legal guardianship or trusteeship, or unable to provide informed consent.\n5. Participation in another interventional clinical study or currently within the exclusion period following a previous ongoing study.\n\n   Specific to the TIPS group\n6. Patients undergoing salvage TIPS placement in the setting of hemorrhagic shock. Specific to the MASLD group\n7. Other etiologies of chronic liver disease, including viral hepatitis, autoimmune liver disease, or hemochromatosis",{"count":65,"type":23},[190],"PORTAL-4D is a prospective, interventional, non-randomized, parallel-group diagnostic study conducted at Pitié-Salpêtrière Hospital (Paris, France).\n\nPortal hypertension is the main driver of hepatic decompensation and is associated with ascites, variceal bleeding, hepatic encephalopathy, and reduced survival. The current gold standard for assessing portal hypertension is the invasive hepatic venous pressure gradient (HVPG) measurement performed via the transjugular route. However, HVPG is invasive, operator-dependent, and limited to specialized centers. A reliable non-invasive alternative is therefore highly needed.\n\n60 adults patients with cirrhosis will be enrolled and divided into two parallel groups: MASLD group (n=24): Patients with compensated cirrhosis related to metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nTIPS group (n=36): Patients with decompensated cirrhosis referred for transjugular intrahepatic portosystemic shunt (TIPS) placement.\n\nThe primary objective is to assess the correlation between invasive HVPG values and 4D-flow MRI parameters. Secondary objectives include evaluating the prognostic value of 4D-flow MRI in predicting portal hypertension-related complications and post-TIPS outcomes within 6 months.\n\nThe study is expected to validate 4D-flow MRI as an non-invasive diagnostic and prognostic tool for portal hypertension, potentially improving patient selection for TIPS and reducing reliance on invasive procedures.",[409,410],"Cirrhosis","Portal Hypertension",[412,413,414,415,416,417,418,419],"4D-Flow MRI","Hepatic Venous Pressure Gradient","Portal Hemodynamics","Noninvasive Liver Imaging","Hepatic Encephalopathy","Portal hypertension complications","TIPS","MASLD",{"date":391,"type":44},{"date":422,"type":23},"2026-06-01",{"date":424,"type":23},"2028-05-01",{"name":50,"class":51},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":431,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":52},"100627495","evaluation-of-fibroscan-performance-in-diagnosing-acute-heart-failure-in-patients-presenting-to-the-emergency-department-100627495","NCT07449377","Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department","FIBROSCAF","Inclusion Criteria:\n\n1. Patients ≥18 years\n2. ED patients presenting with acute dyspnea and absence of any other obvious cause of dyspnea (for example pneumothorax, acute pneumonia, acute coronary syndrome, Covid) …\n3. Social security affiliation (except AME)\n4. Informed consent signed\n\nExclusion Criteria:\n\n1. Known chronic liver disease, defined by a Prothrombic time of \\\u003C 50%, or any former diagnosis of liver fibrosis.\n2. No skin wounds in the abdominal area on which the Fibroscan® will be used\n3. History of liver transplantation\n4. eGFR \\\u003C30 mL\u002Fmin\n5. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom\n6. Pregnancy and breastfeeding\n7. Participation in another interventional trial",{"count":112,"type":23},[190],"Acute heart failure (AHF) is a major cause of acute dyspnea in emergency departments (EDs), driven primarily by venous congestion, which can lead to hepatic congestion and risk of subsequent liver dysfunction. Current diagnostic tools include clinical evaluation, biomarkers, and imaging (Chest X-Ray or echography), are often limited by delayed results, variability, and suboptimal accuracy in emergency settings.\n\nFibroscan®, a non-invasive device originally designed to assess liver stiffness in chronic liver conditions, has shown potential in detecting liver congestion linked to heart failure. Studies have highlighted significant correlations between liver stiffness measurements (LSM) and markers of venous congestion, such as central venous pressure and adverse outcomes in heart failure patients. Preliminary findings suggest that LSM could provide rapid, bedside insights into systemic congestion, offering a promising avenue for improving diagnostic workflows in acute care.\n\nWhile prior research has mainly focused on chronic heart failure or small study populations, further investigation is needed to explore the utility of Fibroscan® in acute presentations of AHF within EDs. This could help address the limitations of existing diagnostic approaches and enhance patient management in time-sensitive environments.",[437],"Acute Heart Failure (AHF)",[439,440,441,442],"Acute heart failure (AHF)","Acute dyspnea","liver stiffness","emergency department",{"date":444,"type":44},"2026-06-25",{"date":446,"type":44},"2026-04-02",{"date":448,"type":23},"2026-11",{"name":50,"class":51},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":61,"minAge":458,"maxAge":459,"enrollmentInfo":460,"targetDuration":4,"studyType":24,"phases":462,"briefSummary":463,"conditions":464,"keywords":466,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":478},"100625810","detection-and-follow-up-of-coronary-lesions-in-hefh-destiny-fh-study-100625810","NCT07427472","\"Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)\"","Detection and Longitudinal Follow-up of Non-calcified and Calcified Coronary Lesions in Heterozygous Familial Hypercholesterolemia (DESTINY-FH)","DESTINY-FH","Inclusion Criteria:\n\n1. Patients with heterozygous familial hypercholesterolemia\n2. Aged 30 to 60 years.\n3. Patients who underwent a CAC score and a coronary CT angiogram at least 5 years ago, exclusively at the same imaging center (ICT de la Pitié Salpetrière).\n4. Patient asymptomatic for exertional chest pain at the time of CCTA\n5. Clinical examination performed\n6. Beneficiary of a social protection scheme or entitled person (excluding AME)\n7. Patient informed and consent form signed\n\nExclusion Criteria:\n\n1. Patient under guardianship, or unable to give consent\n2. Pregnancy, breast-feeding\n3. Technical contraindication: weight \\> 250 kg\n4. Simultaneous participation in other interventional research involving the human body, or period of exclusion following previous research involving the human body still in progress.\n5. Adults subject to a legal protection order\n6. Contraindication to esmolol and\u002For atenolol\n7. Only for patients who need to undergo a CT angiogram and a thoraco-abdominal-pelvic CT scan:\n\n   * Renal insufficiency (LC\\\u003C60)\n   * Unbalanced diabetes when acquiring a previous coronary angioscanner\n   * Personal history of cardiovascular disease and myocardial infarction at the time of CCTA\n   * Contraindication to iodinated contrast media\n   * Patient having already had an adverse event (AE) during the acquisition of a prior coronary angioscanner","30 Years","60 Years",{"count":461,"type":23},300,[190],"This multicenter, non-randomized interventional study aims to assess coronary artery disease progression over 5 years in patients with genetically confirmed heterozygous familial hypercholesterolemia (HeFH), using coronary computed tomography angiography (CCTA).\n\nThe primary endpoint is the visual evaluation of coronary stenosis using CAD-RADS v2.0, identifying changes between baseline (2018-2022) and study inclusion. The study will enroll 300 patients (100 protected, 200 non-protected) from La Pitié-Salpêtrière hospital and Saint Antoine Hospital (Paris). Participation lasts up to one week. Total study duration is 2 years, with extended follow-up through routine care data over 10 years.",[465],"Heterozygous Familial Hypercholesterolemia (HeFH)",[467,468,469,470,471],"Coronary Artery Disease","Atherosclerosis","Coronary Plaque Vulnerability","Cardiovascular Risk","Cardiovascular Events",{"date":391,"type":44},{"date":474,"type":44},"2026-06-19",{"date":476,"type":23},"2036-06-19",{"name":50,"class":51},3,{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":61,"minAge":486,"maxAge":186,"enrollmentInfo":487,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":52},"100618584","assessment-of-body-composition-in-children-treated-with-growth-hormone-for-the-indication-of-isolated-non-acquired-growth-hormone-deficiency-100618584","NCT07333521","Assessment of Body Composition in Children Treated With Growth Hormone for the Indication of Isolated Non-acquired Growth Hormone Deficiency.","COMPOGHD","Inclusion Criteria:\n\n* Patients aged 3 to 17 years inclusive.\n* Confirmed diagnosis of growth hormone deficiency.\n* Indication for treatment with daily or depot growth hormone.\n* Growth hormone treatment naive or already being treated with growth hormone and wishing to change galenical.\n* Holders of parental authority and children or adolescents informed and consenting to participate in the study.\n\nExclusion Criteria:\n\n* BMI greater than +3 SD.\n* Multiple pituitary insufficiency.\n* Acquired growth hormone insufficiency.\n* Patient with type 1 or type 2 diabetes.\n* Known eating disorders.","3 Years",{"count":87,"type":23},"Since 1985, growth hormone deficiency (GHD) in children has been the first condition treated with daily injections of recombinant human growth hormone. Noncompliance with daily growth hormone (GH) therapy is common. Several long-acting growth hormone (LAGH) treatments have recently become available for prescription in France after pivotal phase III trials demonstrated the non-inferiority of these LAGH compared to daily GH administration. To date, published data on LAGH in children are largely limited to clinical trials of GH deficiency (GHD).\n\nContrary to what is observed with daily GH, body mass index increases during the first year of LAGH treatment. With the Somapacitan, the observed mean body mass index (BMI) (SDS) remained within the normal range, but with an increase from -0.17 to +0.39 in the LAGH group and a decrease from -0.25 to -0.49 in the daily GH group. In the Somatrogon study, BMI increased from -0.51 to -0.08 in the somatrogon group, while it decreased from -0.44 to -0.64 in the daily GH group. This increase in BMI was transient and then normalized over the 3-year follow-up.\n\nIn June 2025, recent data from the experience of private endocrinologists in France (AFPEL) on the real-life use of somatrogon were presented at the congress of the French Society of Pediatric Endocrinology and Diabetology. They reported a +1 SD increase in BMI during the first months of treatment in a cohort of 99 children, but an improvement was observed after prolonged treatment.\n\nHowever, significant and persistent weight gain was observed in some patients, with a marked increase in abdominal adiposity. Some discontinued LAGH treatment in favor of daily GH.\n\nLonger-term, real-life data are therefore needed to better understand the changes in BMI in these children treated with LAGH.",[490],"Isolated Non-acquired Growth Hormone Deficiency",[492,493,494,495,496,497],"Isolated non-acquired growth hormone deficiency","Daily growth hormone therapy","Long-acting growth hormone treatments","Body mass index","Auxological measurements","Impedancemetry",{"date":391,"type":44},{"date":500,"type":44},"2026-01-13",{"date":502,"type":23},"2034-01-13",{"name":50,"class":51},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":514,"conditions":515,"keywords":519,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":52},"100612417","evaluation-of-rapid-diagnostic-device-for-the-detection-of-candida-auris-100612417","NCT07253311","Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris","Evaluation of Rapid Diagnostic Device for the Detection of Candida Auris DiagRaMIE C AURIS","DiagRaMIE Caur","Inclusion Criteria:\n\nFrom patients with suspected Candida auris infection:\n\n\\- All isolates from the population that grow on the selective media: Sabouraud-dextrose (40g\u002FL dextrose, 5.0g\u002FL of peptic digest of animal tissue, 5.0 g\u002FL of pancreatic digest of casein, 15.0 g\u002FL of agar and final pH 5.6 ± 0.2) and CHROMagar™ Candida plus (manufactured by CHROMagar™, France). used in the hospital's routine diagnostic process.\n\nFrom patients with suspected Candida auris cutaneous colonization:\n\n\\- All isolates from the population that grow on the selective media: Salt-Sabouraud Dulcitol Broth (SSDB) with chloramphenicol and gentamicin (manufactured by S2 Media, United States), And the media used in the hospital's routine diagnostic process: Sabouraud Dextrose Liquid Medium containing NaCl 10%, chloramphenicol 50 mg\u002FL.\n\nExclusion Criteria:\n\n* NA",{"count":513,"type":23},554,"\"Candida auris is an emerging fungus that can cause severe infections, particularly in hospitalized patients, and is often resistant to multiple antifungal treatments. Rapid and accurate detection of this pathogen is essential to control its spread in healthcare settings.\n\nThis study aims to evaluate the clinical performance of the NG-Test® Candida auris rapid diagnostic test (RDT), developed by CEA and NG Biotech. The test uses immunochromatography and can detect Candida auris in about 15 minutes. Its results will be compared to the reference method, MALDI-TOF, performed on colonies grown from routine patient samples.\n\nBoth retrospective (using stored isolates) and prospective (using new isolates) evaluations will be conducted. The study will measure the sensitivity and specificity of the test, and also include an assessment of its ease of use by laboratory staff. No additional samples will be collected from patients, and all testing will use de-identified isolates to ensure confidentiality.\"",[516,517,518],"Candida Auris Infection","Candida Auris Colonization","Nosocomial Infections",[520,521,522,523,524,525,526,527,528],"Candida auris","Diagnostic Tests","Routine","Immunochromatography","Microbiological Techniques","Sensitivity and Specificity","Microbial Drug Resistance, Fungal","Infection","Control",{"date":391,"type":44},{"date":531,"type":44},"2026-05-25",{"date":533,"type":23},"2026-10-31",{"name":50,"class":51},{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":61,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":546,"briefSummary":547,"conditions":548,"keywords":551,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":52},"100578974","phase-3-efficacy-and-safety-of-tocilizumab-for-acute-chest-syndrome-treatment-in-patients-with-sickle-cell-disease-100578974","NCT06818266","Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease","Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Pediatric and Adult Patients With Sickle Cell Disease","TOCIACS","Inclusion Criteria:\n\n1. SCD patient of all genotypes (SS, SC, S\u002Fβ0 and S\u002Fβ+ or other major SCD syndrome)\n2. Age ≥ 2 years old\n3. Hospitalized for ACS, defined by the WHO as the association of fever and\u002For acute respiratory symptoms with a new pulmonary infiltrate on chest imaging, (X-ray, lung ultrasound, or CT scan)\n4. Requiring supplemental oxygen ≥ 2 L\u002Fmin for SpO2 ≥ 95% or non-invasive respiratory support (high flow nasal oxygen or continuous positive airway pressure or bilevel non-invasive ventilation) or invasive mechanical ventilation or ECMO, for less than 48 hours\n5. Negative pregnancy test for girls or women of childbearing age\n6. Freely given, informed and written consent of patient or legal representatives\n7. Affiliation to the social security (or health insurance)\n8. Effective contraception up to 3 months after the administration of treatment (tocilizumab or placebo)\n\nExclusion Criteria:\n\n1. Impossibility to perform tocilizumab\u002Fplacebo injection within the first 48 hours of supplemental oxygen ≥2L\u002Fmin for SpO2≥95% and\u002For respiratory support (as defined in inclusion criteria n°4). If exchange transfusion is indicated at inclusion, it has to be performed before the injection of tocilizumab\u002Fplacebo.\n2. Known hypersensitivity to tocilizumab or its excipients\n3. Known active current severe bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, and herpes zoster)\n4. Immunization with a live\u002Fattenuated vaccine within the last 4 weeks\n5. Immunomodulatory therapy, anti-rejection therapy, cell depleting therapies and investigational agents within the last 3 months\n6. History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies\n7. History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower gastrointestinal disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions that might predispose a patient to perforations\n8. Evidence of malignant disease or malignancies diagnosed within the last 3 years\n9. Pregnancy or breastfeeding\n10. Imminent and inevitable progression towards death in the opinion of the investigator\n11. Absolute neutrophil count \\\u003C 1.0 G\u002FL or platelets \\\u003C 50 G\u002FL\n12. ALT or AST \\> 5-fold the upper limit of normal\n13. Glomerular Filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002F1,73 m²\n14. Current enrolment in another interventional research concerning a medicinal product for human use","2 Years",{"count":545,"type":23},130,[297],"The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).",[549,550],"Sickle Cell Disease","Acute Chest Syndrome",[552,553,554],"Sickle cell disease","Acute chest syndrome","Tocilizumab",{"date":391,"type":44},{"date":557,"type":44},"2025-08-27",{"date":77,"type":23},{"name":50,"class":51},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":568,"conditions":569,"keywords":571,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":576,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":52},"100540138","translating-articular-biomarkers-into-diagnoses-100540138","NCT06312943","\"Translating Articular Biomarkers Into Diagnoses\"","ARTBioSes","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Inflammatory and non-inflammatory bone and joint diseases requiring synovial fluid aspiration and\u002For joint replacement\n* Collection of non-opposition\n* Affiliated to or beneficiary of social security\n\nExclusion Criteria:\n\n* Inability to speak and\u002For read French\n* Neoadjuvant therapy\n* Patients under tutor or curatorship\n* Protected adults,\n* Patients benefiting of State Medical Aid",{"count":188,"type":23},"Early diagnosis is a key factor in the prevention and management of rheumatic diseases. Rheumatic diseases are classically diagnosed based on criteria combining clinical, biological and radiological features. However, in up to 20% of the cases, diagnoses remain unstated and underlying rheumatic diseases unclassified, which might lead to delayed specific treatment and unfavourable clinical outcomes. In addition, conventional methods could lack sensitivity and specificity for early diagnosis. Biological samples are attractive targets for the early detection of articular damage because they allow for collection of multiple levels of information from the clinic and the laboratory\\]. Biological samples most frequently collected from patients with rheumatic diseases are synovial fluid by joint aspiration, blood by venous puncture and tissue specimen by surgery. The investigators hypothesize that in challenging situations, novel biomarkers detected from synovial fluid or articular tissues using both conventional (e.g. histology, immunodetection, PCR) and innovative (e.g. Raman spectroscopy, nanospectroscopy) laboratory tests may help refining diagnosis and better classifying patients with rheumatic diseases.",[570],"Inflammatory and Non-inflammatory Bone and Joint Diseases",[572,573,574,575,333],"Osteoarthritis","Rheumatoid arthritis","Inflammatory joint disorders","RAMAN spectroscopy",{"date":391,"type":44},{"date":578,"type":44},"2026-06-02",{"date":580,"type":23},"2029-08",{"name":50,"class":51},{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":590,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":52},"100538324","announcement-of-rare-metabolic-diseases-in-systematic-newborn-screening-the-phenylketonuria-experience-100538324","NCT06289348","Announcement of Rare Metabolic Diseases in Systematic Newborn Screening: the Phenylketonuria Experience.","Announcement of Rare Metabolic Diseases as Part of Systematic New-born Screening: the Experience of Phenylketonuria.","ANNPHE","Inclusion Criteria:\n\n* Parent or doctor of a child screened for PKU, born during the inclusion phase of the study\n* Family's first exposure to PKU: the PKU child must be either the eldest or the first sibling to be diagnosed with PKU following neonatal screening\n\nExclusion Criteria:\n\n* Failure to master the French language.\n* Child screened is neither the eldest nor the first sibling to be screened.\n* Refusal by the parents.\n* Any other reason which, in the investigator's judgement, would impair the participants' ability to follow the study protocol, or the interpretation of interview data (e.g. the participating parent has a history of serious psychiatric pathology, one of the parents died at the child's birth, Couples in which one of the members suffers from a known decompensated psychiatric pathology at the time of recruitment. Couples where one of the members is under legal protection or a security measure, etc …).",{"count":376,"type":23},"The aims of this collaborative, interdisciplinary research project are to understand and describe the psychological impact of the announcement of a rare, serious disease present since birth and detected in the context of the systematic neonatal screening (DNS), in terms of the parents' experience, but also on the part of the medical team, in order to improve its process and the support it provides for the announcement of the diagnosis.",[593],"Phenylketonuria",[595,596,597,598,599,600,601,602,603,604],"presymptomatic announcement","systematic neonatal screening","rare diseases","genetic disease","phenylketonuria","care relationship","psychological trauma","psychological impact","parent-child bonding","parenthood",{"date":391,"type":44},{"date":607,"type":44},"2024-05-07",{"date":609,"type":23},"2027-05-20",{"name":50,"class":51},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":61,"minAge":4,"maxAge":186,"enrollmentInfo":619,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":620,"conditions":621,"keywords":623,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":52},"100533633","role-of-bile-acids-and-microbiota-in-clostridioides-difficile-infection-in-ulcerative-colitis-100533633","NCT06228352","Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis","Is Clostridioides Difficile Infection Associated With Changes in Bile Acid Profiles in Children With Ulcerative Colitis","ABRICO","For everyone :\n\nInclusion Criteria:\n\n* Pediatric patients (\\\u003C18 years) consultant or hospitalized in the Gastroenterology department of Necker-Enfants Malades Hospital.\n* Information and consent of parents and the patient\n\nExclusion Criteria:\n\n* Patient who received antibiotic or antifungal treatment in the 4 weeks prior to inclusion.\n* Patients colonized by C. difficile.\n* Pregnant or breastfeeding young girl.\n* Refusal of the protocol by parents or patient.\n\nFor group 1: Patients with active UC\n\nInclusion criteria:\n\n* Patient with UC, whatever the extent, except isolated proctitis (\\\u003C5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria.\n* UC in flare defined by a PUCAI score of between 35 and 65.\n\nNon-inclusion criteria:\n\n* Patient with IBD unclassified or Crohn's disease.\n* Patient with isolated proctitis (\\\u003C5 cm).\n* Colectomized patients.\n* Patients with sclerosing cholangitis associated with their UC or liver disease.\n\nGroup 2: Patients in UC remission\n\nInclusion criteria:\n\n* Patient with UC, whatever the extent, except isolated proctitis (\\\u003C5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria.\n* UC in remission defined by a PUCAI score \\\u003C10.\n\nNon-inclusion criteria:\n\n* Patient with IBD unclassified or Crohn's disease.\n* Patient with isolated proctitis (\\\u003C5 cm).\n* Colectomized patients.\n* Patients with sclerosing cholangitis associated with their UC or liver disease.\n\nGroup 3: Healthy control subjects\n\nInclusion criteria:\n\n\\- Patients hospitalized for an endoscopic assessment to control for abdominal pain, gastroesophageal reflux or polyposis.\n\nNon-inclusion criteria:\n\n* Patient with chronic liver disease.\n* Patient with chronic digestive disease (celiac disease, IBD, chronic chronic).",{"count":376,"type":23},"Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease characterized by chronic inflammation of the colon. Composition of gut microbiota of UC patients is abnormal (dysbiosis).\n\nUlcerative Colitis patients have an increased risk of Clostridioides difficile infection (CDI) and CDI complications (colectomy, death, recurrence). The reason for this increased risk in IBD patients is not fully understood. The decrease in the proportion of secondary bile acids, induced by microbiota dysbiosis in patients with UC could favor C. difficile infection.\n\nThe main objective of the study is to describe the composition of bile acids (primary and secondary) in children followed for UC during relapse with or without CDI and to compare it to children with UC in remission and healthy controls. The composition of fecal microbiota will be also describe to correlate dysbiosis and bile acid abnormalities. And finally some fecal biomarkers will be study : short chain fatty acids, metabolic pathway of Tryptophan, and fecal Calprotectin.",[622],"Ulcerative Colitis",[624,625,626,627],"Ulcerative colitis","Clostridioides difficile infection","Intestinal dysbiosis","Bile acid profiles",{"date":391,"type":44},{"date":630,"type":44},"2026-06-09",{"date":632,"type":23},"2029-06",{"name":50,"class":51},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":61,"minAge":642,"maxAge":186,"enrollmentInfo":643,"targetDuration":4,"studyType":24,"phases":644,"briefSummary":645,"conditions":646,"keywords":648,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":52},"100643995","phase-2-efficacy-and-safety-of-zoledronate-versus-placebo-on-pain-at-week-12-in-pediatric-patients-with-chronic-recurrent-multifocal-osteomyelitis-100643995","NCT07668583","EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS","EFFICACY AND SAFETY OF ZOLEDRONATE VERSUS PLACEBO ON PAIN AT WEEK 12 IN PEDIATRIC PATIENTS WITH CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS RESISTANT TO NON-STEROIDAL ANTI-INFLAMMATORY DRUG","POMREP","Inclusion Criteria:\n\n* aged ≥4 and \\\u003C17 years for whom:\n* Physician-confirmed diagnosis of CRMO according to Jansson's criteria, with compatible MRI findings. Having lesions on MRI within 12 weeks prior to inclusion and clinically active disease defined by at least one of 2 criteria: patient\u002Fparent VAS (pain) superior or equal to 30\u002F100 and\u002For physician VAS superior or equal to 30\u002F100 after failure of at least 4 weeks of NSAIDs at a stable dose\n* Written informed consent signed by the parents (the child may sign the consent if they wish, but their signature is not mandatory)\n* Having had a dental review within 3 months prior to inclusion, with completion of any necessary invasive dental work before the first dose of zoledronate.\n\nExclusion Criteria:\n\n* History of malignancy or current tumour\n* History of seizure\n* Current infectious osteomyelitis\n* Contraindication to the study drug\n* Hypersensitivity to the active substance, to other bisphosphonates, or to any excipient (sodium hydroxide, hydrochloric acid for pH adjustment, water for injection) ;\n* Hypocalcemia ;\n* Severe renal impairment with creatinine clearance \\\u003C 35 ml\u002Fmin ;\n* Prior treatment with bisphosphonates and\u002For biotherapy within 6 months prior to inclusion.\n* History of HIV, HBV, or HCV infection.\n* Congenital or acquired prolonged QT interval (\\>0.44 seconds) on ECG.\n* Clinically significant vertebral deformities, including vertebral fracture and\u002For angular kyphosis with risk of spinal cord compression.\n* Suspected or confirmed tuberculosis.\n* History of renal or hepatic insufficiency.\n* Already enrolled in another interventional study.\n* Pregnant or breastfeeding participants\n* Not affiliated with the French social security system.\n* Patient or legal guardians with limited understanding of the French language\n* Serum 25-hydroxy vitamin D level \\\u003C30 ng\u002FmL at screening. Participants may be re-screened after correction of vitamin D deficiency.","4 Years",{"count":166,"type":23},[27],"Chronic recurrent multifocal osteomyelitis (CRMO) is a rare auto-inflammatory bone disease that primarily affects children and\u002For adolescents at a median age of 10 years. Until now, there is no consensus regarding the treatment of CRMO. Non-steroidal anti-inflammatory drugs (NSAIDs) are considered the first line of therapy with remission in approximately 30% of cases. If unsuccessful, several treatments are tried in addition to NSAIDs, including bisphosphonates and anti-TNFs.\n\nThe effectiveness of bisphosphonates (including zoledronate) has been reported in clinical cases and\u002For retrospective series. They are said to be particularly effective in multifocal forms, mandibular and\u002For vertebral involvement, but no controlled trials have been conducted. Bisphosphonates have even been proposed as first-line therapy in spinal involvement. The only prospective study, is a phase II trial currently underway in Denmark to study the efficacy of zoledronate (NCT02594878) versus placebo in SAPHO (acronym, standing for Synovitis - Acne - Pustulosis - Hyperostosis - Osteitis) patients considered to be a very similar form of CRMO occurring in adults.\n\nIn this context, this study proposes evaluate the efficacy of zoledronate compared to placebo in reducing pain at week 12 in children aged ≥4 and \\\u003C17 years with NSAID-resistant CRMO. Zoledronate will be administered in three escalating doses: 0.025 mg\u002Fkg at baseline (W0), 0.05 mg\u002Fkg at week 12 (W12), and 0.05 mg\u002Fkg at week 24 (W24). In addition to pain reduction, improvements in MRI findings will be observed, biological markers of inflammation, and quality of life in the zoledronate group. Although subjective, pain reduction remains the most widely used criterion in clinical practice to assess therapeutic efficacy. Zoledronate efficacy will therefore be assessed by the change in standardized pain score (0-10 scale) from baseline to week 12 as the primary endpoint, with additional pain assessments at weeks 4, 24, and 36 as secondary endpoints.",[647],"Osteomyelitis Chronic",[649],"Osteomyelitis","2026-06-21",{"date":444,"type":44},{"date":653,"type":23},"2026-09-15",{"date":655,"type":23},"2029-12-31",{"name":50,"class":51},{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":61,"minAge":62,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":666,"conditions":667,"keywords":669,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":673,"startDateStruct":674,"completionDateStruct":675,"leadSponsor":677,"locationsCount":4},"100644636","epigenomic-profiling-of-circulating-cell-free-dna-cfdna-to-characterize-the-dynamic-evolution-of-molecular-subtypes-in-extensive-stage-small-cell-lung-cancer-during-first-line-chemoimmunotherapy-100644636","NCT07670442","Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy","Profilage épigénomique de l'ADN Circulant Libre (cfDNA) Pour caractériser l'évolution Dynamique Des Sous-types moléculaires du Cancer du Poumon à Petites Cellules à un Stade étendu au Cours de la chimiothérapie-immunothérapie de première Ligne","EPICIRC-SCLC","Inclusion Criteria:\n\nHistologically or cytologically confirmed SCLC\n\nIndication for first-line systemic anti-tumor treatment with chemo-immunotherapy as decided in a multidisciplinary tumor board.\n\nPatient's ability to comply with the required study follow-up.\n\nAge ≥ 18 years.\n\nPatient affiliated with a social security scheme.\n\nPatient managed in the Thoracic Oncology department of Cochin Hospital or HEGP.\n\nPatient able to understand the participant information sheet.\n\nExclusion Criteria:\n\nExpressed refusal at the time of receiving the information sheet.\n\nPerson not proficient in the French language.\n\nPerson deprived of liberty or under legal protection (including guardianship or curatorship).\n\nPregnancy or breastfeeding.",{"count":188,"type":23},"The EPICIRC SCLC project aims to improve our understanding and treatment of extensive-stage small cell lung cancer (ES SCLC), the most aggressive form of lung cancer that accounts for 15% of all cases. Despite current treatments, which combine chemotherapy with immunotherapy, the outlook for patients remains poor, with an average survival of just 12 months. Recent research has shown that this cancer can be classified into four subtypes, which respond differently to anti-cancer treatments. However, these subtypes may change over time, particularly during chemotherapy, which could explain why many patients eventually become resistant to treatment. Understanding how these subtypes evolve could pave the way for better treatment strategies, but it has been difficult to study these changes because new tumor samples are rarely collected after a patient is diagnosed. The EPICIRC SCLC project tackles this challenge by using liquid biopsies, a minimally invasive technique that analyzes circulating free DNA (cfDNA) found in patients blood. This approach allows to monitor changes in the tumor's molecular profile over time without needing additional tissue samples. By collecting and analyzing blood samples from patients at three key points-before treatment, after four cycles of chemo-immunotherapy, and at disease progression-the project aims to track the evolution of the tumor's molecular subtypes and identify patterns associated with treatment resistance. Using advanced epigenomic technologies, we will study how genes are regulated and how their activity changes during treatment. This will provide a detailed map of the tumor's molecular evolution and could uncover new targets for future therapies. In the long term, these findings would lead to more personalized treatment strategies, helping clinicians select therapies based on the specific molecular profile of each patient's cancer at different stages of their treatment.",[668],"Small Cell Lung Cancer",[670,671,672],"liquid biopsy","cell free DNA","Smal Cell Lung Cancer",{"date":334,"type":44},{"date":125,"type":23},{"date":676,"type":23},"2030-07-01",{"name":50,"class":51},""]